NasdaqGS:RXRXBiotechs
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Nvidia Exit And ARK Invest Share Purchase
Nvidia’s decision to fully exit Recursion Pharmaceuticals (RXRX), followed almost immediately by ARK Invest buying 1.25 million shares, has thrown a spotlight on the stock and its AI-driven drug discovery approach.
See our latest analysis for Recursion Pharmaceuticals.
Those opposing moves by Nvidia and ARK come after a weak stretch for Recursion, with a 30 day share price return of 27.70% decline and a 1 year total shareholder return of 62.00% decline, pointing to fading momentum despite...